PMID- 29765173
OWN - NLM
STAT- Publisher
LR  - 20240227
IS  - 1804-7521 (Electronic)
IS  - 1213-8118 (Linking)
DP  - 2018 May 15
TI  - Hemodiafiltration and plasma levels of axitinib in a patient with metastatic 
      renal clear cell carcinoma.
LID - 10.5507/bp.2018.021 [doi]
AB  - BACKGROUND: The standard treatment for metastatic renal cancer is based on 
      vascular endothelial growth factor (VEGF) and mammalian target of rapamycin 
      (mTor) inhibitors. Compared to other advanced tumors, the treatment of renal 
      cancer is highly affected by impaired renal function; therefore, patients with 
      severe renal insufficiency, including patients on hemodialysis, are generally 
      excluded from clinical trials. CASE REPORT: In the present manuscript we present 
      the case of a renal cancer patient who underwent bilateral nephrectomy and 
      received two lines of treatment. We hypothesized that axitinib, a tyrosine kinase 
      inhibitor, would have a similar plasma concentration to patients without 
      hemodialysis and that the levels before and after hemodiafiltration will not 
      differ significantly, as observed in other targeted therapies. CONCLUSION: The 
      observed axitinib concentrations were at least an order of magnitude lower than 
      expected based on the literature and measurements in other patients. The present 
      case report indicates a potential risk of axitinib underdosing in patients on 
      hemodiafiltration with the standard dose; therefore, drug dosage may need to be 
      corrected based on the plasma levels of axitinib.
FAU - Kopecky, Jindrich
AU  - Kopecky J
AD  - Department of Clinical Oncology and Radiotherapy, University Hospital Hradec 
      Kralove and Faculty of Medicine in Hradec Kralove, Charles University, Czech 
      Republic.
FAU - Ticha, Alena
AU  - Ticha A
AD  - Department of Research and Development, University Hospital Hradec Kralove, Czech 
      Republic.
FAU - Janeckova, Hana
AU  - Janeckova H
AD  - Laboratory for Inherited Metabolic Disorders, Department of Clinical 
      Biochemistry, University Hospital Olomouc, Czech Republic.
AD  - Institute of Molecular and Translational Medicine, Faculty of Medicine and 
      Dentistry, Palacky University Olomouc, Czech Republic.
FAU - Bohuslav, Melichar
AU  - Bohuslav M
AD  - Department of Clinical Oncology and Radiotherapy, University Hospital Hradec 
      Kralove and Faculty of Medicine in Hradec Kralove, Charles University, Czech 
      Republic.
AD  - Department of Oncology, Faculty of Medicine and Dentistry, Palacky University 
      Olomouc, Czech Republic.
LA  - eng
PT  - Journal Article
DEP - 20180515
PL  - Czech Republic
TA  - Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub
JT  - Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, 
      Czechoslovakia
JID - 101140142
EDAT- 2018/05/17 06:00
MHDA- 2018/05/17 06:00
CRDT- 2018/05/17 06:00
PHST- 2018/05/17 06:00 [entrez]
PHST- 2018/05/17 06:00 [pubmed]
PHST- 2018/05/17 06:00 [medline]
AID - 10.5507/bp.2018.021 [doi]
PST - aheadofprint
SO  - Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2018 May 15. doi: 
      10.5507/bp.2018.021.